NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis $0.72 +0.00 (+0.31%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Clearmind Medicine Stock (NASDAQ:CMND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Clearmind Medicine alerts:Sign Up Key Stats Today's Range$0.71▼$0.7450-Day Range$0.72▼$1.9652-Week Range$0.71▼$480.00Volume83,583 shsAverage Volume960,487 shsMarket Capitalization$732.36 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Clearmind Medicine Inc. is a biotechnology company focused on developing psychedelic-derived therapeutics for behavioral and mental health disorders. Its research programs are designed to address conditions with significant unmet medical needs, including alcohol use disorder and binge-related behaviors. The company’s pipeline includes investigational compounds based on novel psychedelic molecules, including 5-methoxy-2-aminoindane (MEAI). Clearmind is studying these compounds for their potential to reduce harmful consumption patterns and support improved mental health outcomes. Its activities include preclinical research, drug discovery and the advancement of candidates toward clinical development. Clearmind Medicine is incorporated in Canada and has conducted research and development activities internationally, including in Israel. The company’s programs remain investigational, and its product candidates have not been approved for commercial sale by regulatory authorities.AI Generated. May Contain Errors. Read More Clearmind Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCMND MarketRank™: Clearmind Medicine scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Clearmind Medicine. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearmind Medicine is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearmind Medicine is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearmind Medicine has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.51% of the float of Clearmind Medicine has been sold short.Short Interest Ratio / Days to CoverClearmind Medicine has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearmind Medicine has recently increased by 41.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearmind Medicine does not currently pay a dividend.Dividend GrowthClearmind Medicine does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment-1.00 News SentimentClearmind Medicine has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Clearmind Medicine this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for CMND on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Clearmind Medicine insiders have not sold or bought any company stock.Percentage Held by Institutions96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Clearmind Medicine's insider trading history. Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMND Stock News HeadlinesClearmind Reports U.S. Patent Applications For Drug Combinations In Mental HealthSeptember 26, 2026 | rttnews.comClearmind Medicine Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine CombinationsSeptember 24, 2026 | marketscreener.comMHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.October 2 at 1:00 AM | Base Camp Trading (Ad)NeuroThera Labs Inc. And Clearmind Medicine Inc. Highlight Enhancement Of U.S. Patent Portfolio Through Collaboration Covering LSD, Ketamine And Ibogaine CombinationsSeptember 23, 2026 | marketscreener.comMClearmind Medicine Announces U.S. Publication of Patent Applications Covering LSD, Ketamine and Ibogaine Combinations with N-AcylethanolaminesSeptember 23, 2026 | quiverquant.comQClearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine CombinationsSeptember 23, 2026 | globenewswire.comClearmind Medicine Testifies at FDA Psychedelic Hearing on Patient Access and MEAI Clinical Trial InsightsSeptember 17, 2026 | quiverquant.comQClearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.September 17, 2026 | globenewswire.comSee More Headlines CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed this year? Clearmind Medicine's stock was trading at $18.10 at the beginning of the year. Since then, CMND stock has decreased by 96.0% and is now trading at $0.73. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) announced its quarterly earnings data on Thursday, September, 10th. The company reported ($0.57) EPS for the quarter. When did Clearmind Medicine's stock split? Clearmind Medicine shares reverse split on the morning of Tuesday, November 28th 2023.The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an IPO on Tuesday, November 15th 2022. The company issued 1,300,000 shares at $6.00-$8.00 per share. Aegis Capital Corp. served as the underwriter for the IPO. How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearmind Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF). Company Calendar Last Earnings9/10/2026Today10/02/2026Fiscal Year End10/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CMND's financial health is in the Red zone, according to TradeSmith. CMND has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CMND CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($40.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-88.53% Return on Assets-61.62% Debt Debt-to-Equity Ratio0.01 Current Ratio4.31 Quick Ratio4.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.71 per share Price / Book0.06Miscellaneous Outstanding Shares1,020,000Free FloatN/AMarket Cap$734.40 thousand OptionableNot Optionable Beta0.94 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CMND) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
